Meitav Dash Investments Ltd. purchased a new stake in Urogen Pharma Ltd (NASDAQ:URGN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 412,882 shares of the company’s stock, valued at approximately $15,363,000.
Several other institutional investors also recently added to or reduced their stakes in the company. Lyon Street Capital LLC raised its stake in shares of Urogen Pharma by 35.6% in the 4th quarter. Lyon Street Capital LLC now owns 56,617 shares of the company’s stock valued at $2,107,000 after acquiring an additional 14,876 shares during the period. Millennium Management LLC purchased a new stake in shares of Urogen Pharma in the 4th quarter valued at approximately $427,000. Bainco International Investors raised its stake in shares of Urogen Pharma by 44.9% in the 4th quarter. Bainco International Investors now owns 104,961 shares of the company’s stock valued at $5,204,000 after acquiring an additional 32,500 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Urogen Pharma in the 4th quarter valued at approximately $277,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Urogen Pharma in the 4th quarter valued at approximately $234,000. 50.49% of the stock is currently owned by institutional investors and hedge funds.
Urogen Pharma Ltd (URGN) opened at $53.24 on Tuesday. Urogen Pharma Ltd has a twelve month low of $13.01 and a twelve month high of $58.66.
Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.09). The company had revenue of $0.33 million for the quarter. sell-side analysts expect that Urogen Pharma Ltd will post -2.46 earnings per share for the current fiscal year.
URGN has been the subject of a number of research reports. Jefferies Group restated a “buy” rating on shares of Urogen Pharma in a report on Monday. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $65.00 price objective on shares of Urogen Pharma in a report on Friday. Finally, Oppenheimer set a $62.00 price objective on shares of Urogen Pharma and gave the company a “buy” rating in a report on Thursday, March 15th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $43.33.
COPYRIGHT VIOLATION NOTICE: “Meitav Dash Investments Ltd. Purchases Shares of 412,882 Urogen Pharma Ltd (URGN)” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2018/03/20/meitav-dash-investments-ltd-purchases-shares-of-412882-urogen-pharma-ltd-urgn.html.
Urogen Pharma Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.